| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Amortization of debt discount and financing costs | NaN | 0 | 0 |
| Net loss | 11,896 | -5,181 | -10,823 |
| Depreciation and amortization expense | -802 | 427 | 801 |
| Stock-based compensation | -1,427 | 529 | 1,129 |
| Change in fair value of other liabilities and derivatives | -132 | 100 | -16 |
| Prepaid expenses and other current assets | 28 | -118 | 156 |
| Accounts payable | 1,156 | -191 | -733 |
| Accrued expenses and other current liabilities | 727 | 264 | -1,449 |
| Operating lease right of use liability | 743 | -304 | -764 |
| Net cash used in operating activities | 12,133 | -4,238 | -12,011 |
| Purchases of machinery and equipment | -86 | 27 | 64 |
| Net cash used in investing activities | 86 | -27 | -64 |
| Proceeds from exercise of common stock warrants | NaN | 0 | 0 |
| Proceeds from issuance of noncontrolling interest in nova cell | NaN | 0 | NaN |
| Related party proceeds from issuance of loan payable | NaN | 0 | 0 |
| Repayment of principal on related party term notes payable | NaN | 375 | 1,625 |
| Proceeds from issuance of convertible notes payable | NaN | 0 | 0 |
| Repayment of principal on term notes payable | NaN | 0 | 200 |
| Proceeds from issuance of common shares and warrants per subscription agreement | NaN | 0 | NaN |
| Repayment of principal on related party bridge loan payable | NaN | 0 | 200 |
| Proceeds from issuance of promissory note | NaN | 0 | NaN |
| Repayment of convertible note payable | NaN | 0 | 0 |
| Payment of debt issuance costs | NaN | 0 | 0 |
| Proceeds from public offerings | NaN | 6,090 | 6,573 |
| Proceeds from warrant inducement financing | NaN | 4,136 | 0 |
| Proceeds from registered direct offering | NaN | 0 | 3,503 |
| Proceeds from public offerings | 5,369 | NaN | NaN |
| Proceeds from exercise of pre-funded warrants | 0 | 2 | 3 |
| Repayment of financing lease obligations | -19 | 29 | 34 |
| Payment of financing costs | -554 | 344 | 381 |
| Net cash provided by financing activities | -11,960 | 9,480 | 7,639 |
| Effect of exchange rate changes on cash | -13 | 0 | 6 |
| Net increase in cash and restricted cash | 246 | 5,215 | -4,430 |
| At beginning of the period | 10,594 | 9,809 | NaN |
| At end of the period | 6,850 | 10,594 | NaN |
Calidi Biotherapeutics, Inc. (CLDWW)
Calidi Biotherapeutics, Inc. (CLDWW)